China-Biotics reported positive financial results for its 2009 fiscal year, which ended in March. Sales rose 28% to $54.2 million, and non-GAAP net income climbed 19% to $16.9 million, a very healthy margin of 31%. Revenues were in line with analysts’ expectations, but net income, which equates to 99 cents per diluted share, beat the street estimate of 83 cps. More details...

Stock Symbol: (NSDQ: CHBT)